Telomir Pharmaceuticals (TELO) Competitors $1.20 +0.02 (+1.27%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. SCPH, NBTX, MNPR, DRUG, IMAB, CRGX, GNFT, LRMR, KOD, and CTORShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include scPharmaceuticals (SCPH), Nanobiotix (NBTX), Monopar Therapeutics (MNPR), Bright Minds Biosciences (DRUG), I-Mab (IMAB), CARGO Therapeutics (CRGX), GENFIT (GNFT), Larimar Therapeutics (LRMR), Kodiak Sciences (KOD), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors scPharmaceuticals Nanobiotix Monopar Therapeutics Bright Minds Biosciences I-Mab CARGO Therapeutics GENFIT Larimar Therapeutics Kodiak Sciences Citius Oncology Telomir Pharmaceuticals (NASDAQ:TELO) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability. Do insiders & institutionals believe in TELO or SCPH? 89.5% of scPharmaceuticals shares are owned by institutional investors. 4.8% of scPharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend TELO or SCPH? Telomir Pharmaceuticals presently has a consensus price target of $15.00, indicating a potential upside of 1,155.23%. scPharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 252.64%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Telomir Pharmaceuticals is more favorable than scPharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, TELO or SCPH? Telomir Pharmaceuticals has higher earnings, but lower revenue than scPharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$16.53M-$0.42-2.85scPharmaceuticals$36.33M5.77-$85.15M-$1.91-2.08 Does the media favor TELO or SCPH? In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than scPharmaceuticals. MarketBeat recorded 2 mentions for Telomir Pharmaceuticals and 0 mentions for scPharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.34 beat scPharmaceuticals' score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Telomir Pharmaceuticals Neutral scPharmaceuticals Neutral Is TELO or SCPH more profitable? Telomir Pharmaceuticals has a net margin of 0.00% compared to scPharmaceuticals' net margin of -216.24%. scPharmaceuticals' return on equity of -594.07% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -2,009.40% -1,009.72% scPharmaceuticals -216.24%-594.07%-73.54% Which has more volatility & risk, TELO or SCPH? Telomir Pharmaceuticals has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. SummaryTelomir Pharmaceuticals and scPharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.56M$2.41B$5.50B$9.01BDividend YieldN/A1.77%5.39%4.11%P/E Ratio-2.858.9727.4220.07Price / SalesN/A467.40398.50109.13Price / CashN/A151.5836.1356.90Price / Book59.754.618.015.70Net Income-$16.53M$31.34M$3.16B$248.47M7 Day Performance-29.71%0.86%2.08%2.92%1 Month Performance-41.42%7.90%4.38%5.77%1 Year Performance-68.13%1.89%35.81%21.39% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals2.6753 of 5 stars$1.20+1.3%$15.00+1,155.2%-70.9%$35.56MN/A-2.851SCPHscPharmaceuticals4.5547 of 5 stars$3.96+3.4%$14.00+253.5%-4.0%$209.05M$36.33M-2.0730NBTXNanobiotix2.4717 of 5 stars$4.41-0.2%$8.00+81.4%-7.1%$207.86M-$11.61M0.00100Gap UpMNPRMonopar Therapeutics3.0304 of 5 stars$33.30+4.6%$56.50+69.7%+876.7%$203.80MN/A-9.5710DRUGBright Minds Biosciences3.1689 of 5 stars$28.00+3.4%$83.25+197.3%+2,446.4%$197.12MN/A-77.78N/ANews CoveragePositive NewsAnalyst ForecastIMABI-Mab3.0587 of 5 stars$2.37-3.7%$5.50+132.1%+44.9%$193.53M$3.89M0.00380News CoverageCRGXCARGO Therapeutics2.5371 of 5 stars$4.18+1.2%$15.00+258.9%-72.2%$192.74MN/A-0.90116GNFTGENFIT1.9575 of 5 stars$3.85+1.0%$13.00+237.7%-4.4%$192.50M$76.77M0.00120Gap UpLRMRLarimar Therapeutics1.7566 of 5 stars$2.99+23.6%$18.50+518.7%-59.7%$191.44MN/A-2.0130High Trading VolumeKODKodiak Sciences4.1451 of 5 stars$3.61-0.6%$9.00+149.3%+71.0%$190.48MN/A-0.9990Gap UpCTORCitius Oncology0.1619 of 5 stars$2.66+6.4%$3.00+12.8%N/A$190.33MN/A0.00N/AGap Down Related Companies and Tools Related Companies scPharmaceuticals Alternatives Nanobiotix Alternatives Monopar Therapeutics Alternatives Bright Minds Biosciences Alternatives I-Mab Alternatives CARGO Therapeutics Alternatives GENFIT Alternatives Larimar Therapeutics Alternatives Kodiak Sciences Alternatives Citius Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TELO Stock Alerts